Cardiovascular Systems Inc  

(Public, NASDAQ:CSII)   Watch this stock  
Find more results for CSII
29.33
-0.09 (-0.31%)
Aug 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 29.18 - 29.73
52 week 18.83 - 37.73
Open 29.42
Vol / Avg. 114,175.00/179,150.00
Mkt cap 910.39M
P/E     -
Div/yield     -
EPS -1.24
Shares 30.88M
Beta 0.73
Inst. own 71%
Oct 28, 2014
Q1 2015 Cardiovascular Systems Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Aug 6, 2014
Q4 2014 Cardiovascular Systems Inc Earnings Call - Webcast
Aug 6, 2014
Q4 2014 Cardiovascular Systems, Inc. Earnings Release
Jun 11, 2014
Cardiovascular Systems Inc at William Blair & Company LLC Growth Stock Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2014
Net profit margin -24.34% -25.83%
Operating margin -24.15% -24.51%
EBITD margin - -24.51%
Return on average assets -21.02% -25.32%
Return on average equity -25.05% -32.24%
Employees 345 -
CDP Score - -

Address

651 CAMPUS DRIVE
ST. PAUL, MN 55112
United States - Map
+1-651-2591600 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cardiovascular Systems, Inc. (CSI) is a medical device company. CSI is focused on developing and commercializing minimally invasive treatment solutions for vascular disease. Interventional endovascular treatment of peripheral artery disease (PAD) is the Company�s initial area of focus. The Company�s primary products include the Diamondback 360 PAD System (Diamondback 360), Diamondback Predator 360 PAD System (Predator 360) and Stealth 360 PAD System (Stealth 360). Diamondback 360, the Predator 360 and the Stealth 360 collectively are referred to as PAD Systems. As of June 30, 2011, the PAD Systems had been utilized in more than 50,000 procedures. It uses internally manufactured and externally sourced to manufacture the PAD Systems. In addition to the PAD Systems, CSI is expanding its product portfolio through internal product development and establishment of business relationships with other medical device companies.

Officers and directors

Glen D. Nelson M.D. Independent Chairman of the Board
Age: 76
Bio & Compensation  - Reuters
David L. Martin President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Laurence L. Betterley Chief Financial Officer
Age: 59
Bio & Compensation  - Reuters
Kevin J. Kenny Executive Vice President - Sales & Marketing
Age: 48
Bio & Compensation  - Reuters
Robert J. Thatcher Executive Vice President
Age: 58
Bio & Compensation  - Reuters
Paul Koehn Senior Vice President - Quality and Operations
Age: 50
Bio & Compensation  - Reuters
James E. Flaherty Chief Administrative Officer, Secretary
Age: 59
Bio & Compensation  - Reuters
Scott A. Bartos Independent Director
Age: 50
Bio & Compensation  - Reuters
Brent G. Blackey Independent Director
Age: 55
Bio & Compensation  - Reuters
Edward M. Brown Independent Director
Age: 50
Bio & Compensation  - Reuters